The OCRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ovarian cancer. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.
A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03...) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 OCRP Areas of Emphasis.
Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through non-invasive techniques and may drive the development of precision imaging and advanced targeted therapies.
Deadlines:
• Required Pre-Application Deadline: June 3, 2024
• Application Submission Deadline: Aug 6, 2024
To meet the intent of the funding opportunity, applications for the FY24 OCRP Clinical Trial Award must address a critical component of at least one of the Areas of Emphasis listed below:
• Understand the basic biology and etiology of ovarian cancer initiation, progression, metastasis, recurrence, genetics, proteogenomic and other critical events.
• Develop novel therapeutic strategies for treatment.
• Investigate innovative approaches for ovarian cancer prevention.
• Identify and develop new strategies for screening, early-stage detection, accurate diagnosis, and prognosis.
• Identify and implement strategies to improve the survivorship and quality of life.
• Address health disparities.
• Improve precision medicine.
Independent investigators at all academic levels (or equivalent) are eligible to be named as a PI on an application. An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by or affiliated with an eligible organization.
The anticipated direct costs budgeted for the entire period of performance for an FY24 OCRP Clinical Trial Award should not exceed $2M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.